dCROX and ROX Indices Predict Clinical Outcomes in Patients with COVID-19 Pneumonia Treated with High-Flow Nasal Cannula Oxygen Therapy
Table 1
Baseline characteristics of hospitalized patients with COVID-19 pneumonia receiving high-flow nasal cannula treatment.
Characteristic
Data (N = 106)
Age (years)
62.1 ± 16.2
Male
52 (49.1)
Female
54 (50.9)
Body mass index (kg/m2)
27.3 ± 5.6
Comorbidity
Hypertension
50 (47.2)
Diabetes
38 (35.8)
Dyslipidemia
33 (31.1)
Chronic kidney disease
11 (10.4)
Cardiovascular disease
5 (4.7)
Malignancy
4 (3.8)
Cerebrovascular disease
3 (2.8)
COPD
3 (2.8)
Asthma
2 (1.9)
Laboratory data
Hemoglobin (g/dL)
12.9 ± 2.1
White blood cells count (μL)
7,276.4 ± 3,478.7
Neutrophils (%)
73.5 ± 13.1
Lymphocytes (%)
17.7 ± 10.4
Platelet (μL)
207,679.2 ± 93,513.9
CRP at admission (mg/L)
92.0 ± 63.4
CRP at 72 hours (mg/L)
52.0 ± 47.3
SpO2/FiO2 ratio
276.1 ± 124.8
Outcomes of weaning from HFNC
Success within 7 days
38 (35.8)
Success within 14 days
65 (61.3)
Data shown as n (%) or the mean ± SD. COPD = chronic obstructive pulmonary disease, CRP = C-reactive protein, FiO2 = fraction of inspired oxygen, HFNC = high-flow nasal cannula, and SpO2 = oxygen saturation.
